Академический Документы
Профессиональный Документы
Культура Документы
Having
11
2006 Ranbaxy Acquired Unbranded Generic Business Of GSK In Italy And Spain 2003 Receives The Economic Times Award For Corporate Excellence For The Company Of The Year 2002-03 1998 Ranbaxy Enters USA Worlds Largest Pharma Market, With Products Under Own Name 1995 Acquisition Of Ohm Laboratories In Us
1992 Company Enters Into An Agreement To Setup A Joint Venture In China Ranbaxy Ltd. 1985 Ranbaxy Research Foundation Is Established
2005
HISTORY OF DAIICHI-SANKYO
DAIICHI SANKYO SANKYO Shoten, SANKYOs predecessor company, established in Japan SANKYO establishes SANKYO Europe in Ds Germany Laboratories Fornet S.A., France
1985
2002 Acquisition of
15th Largest drug maker in the world Market Capitalization 30 Billion Low cost production
Synergies
Considering that Ranbaxy is a generics company and Daiichi Sankyo an
innovator company, both the businesses complement each other with negligible overlap.(Daiichi will support Ranbaxy's R&D efforts and contract research business)
Ranbaxy provides a low cost manufacturing set-up to Daiichi Sankyo. Ranbaxy geographically diversified presence across the globe will enable it
to provide a wider reach to Daiichi Sankyo' product portfolio, including India. market holds good opportunities.
Ranbaxy has a small presence in the Japanese market where the generics
Contd.
The deal strengthened the financials of Ranbaxy (making it debt free and
cash rich) and help it grow aggressively -organic.
Ranbaxy bypassed a lot of European and U.S. companies that were finding
it difficult to enter the Japanese market, where safety and testing requirements are a lot higher.
This deal made the amalgamated company to be the 15th largest pharma
company in the world.
Pre Merger Value of both the firms + Post Merger Number of shares Synergy
= Post Merger Stock Price The below equation solves for the minimum required synergy:
Acceleration of innovation drug creation by optimizing value chain efficiency. The acquisition of Ranbaxy by Daichi represents a major entry for the Japanese firm into
the high growth business areas of generic drug. The acquisition shows that global pharma companies are making efforts to cope up with strong generic drug makers.
The Deal
Daiichi-Sankyo acquired 34.8% stake in Ranbaxy on 11th June, 2008 It made an open offer to the Ranbaxy shareholders for another 20%
Transactional Process
INSURANCE COMPANY
F.I.I GENERAL PUBLIC
14.39
12.42 12.1
9.19
4.41 19.53
(36.13)
(64.49) 61.40
Dec ' 07
4,071.29
Dec ' 06
3,973.56
Dec ' 05
3,490.13
Sales
4,784.76
Operating profit
Interest Gross profit
822.89
239.75
546.87
559.45
65.76
(109.85)
893.40
93.43
58.10
26.41
1,210.12
(562.40)
893.14
580.92
249.01
EPS (Rs)
13.61
(24.56)
16.56
10.37
6.01
Total
488,354
(45.0)
Goodwill
408.7
83.69 %
Total consideration
488.3
Valuation of 100% equity of Ranbaxy as per the 30982 crores deal Enterprise valuation of Ranbaxy (on a fully diluted basis) Market capitalization of Ranbaxy as on 30th May 2009 (conclusion of deal) $ 8.5 billion 10434 crores
Global down turn due to the financial crisis has made Daiichi take a huge hit on its balance sheet due to the acquisition of Ranbaxy.
Reason
0
17.5 0.8
411.3
Financing of Deal
Daiichi-Sankyo funded the acquisition through debt and existing cash reserves. Daiichi-Sankyo has a taken a short and long term loans of 240 billion yens.
Post Acquisition Objectives
To develop new drugs to fill the gaps and take advantage of Ranbaxys strong areas.
The stock ended almost flat at Rs 560.80 on June 11th . June 13- it spiked to Rs 660 and settled at 567.75 points, up a
mere 0.15%.
yr. Dec. 07
% diff.
Dec. 08
Dec. 09
% diff.
4784.76
37.09
Operating profit
65.76
546.87
731.61
239.75
264.58
822.89
1151.35
Interest
26.41
93.43
253.76
893.40
3282.8
(109.85)
(515)
Gross profit
249.01
893.14
258.67
(562.40)
(221)
1210.12
385.97
EPS (Rs)
6.01
16.56
175.54
(24.56)
13.61
126.45
6000
5000
4000
3000
2000
1000
0 Base yr. 05 -1000 Dec. 06 % diff. Dec. 07 % diff. Dec. 08 % diff. Dec. 09 % diff.